Alvotech WT (ALVOW)

$3.41 +0.36 (11.80%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	N/A
Revenue (ttm)	91.43M
Net Income (ttm)	-551.73M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	11,000
Avg Vol	4,012
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	73%
Beta	N/A
Analysts	Sell
Price Target	N/A

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosim...

Website: www.alvotech.com

Address:

9, Rue de Bitbourg, Luxembourg, Luxembourg